发布: 2019年04月20日第9卷第8期 DOI: 10.21769/BioProtoc.3217 浏览次数: 4668
评审: Alak MannaVarun KesherwaniWathsala Wijayalath
Abstract
Intranasal administration of vaccine adjuvants directly deliver therapeutic agents to the lungs to induce potent lung mucosal immune responses. Cyclic di-GMP (CDG) is a promising mucosal vaccine adjuvant candidate capable of inducing protective immunity. This protocol describes an in vivo approach to induce and detect mucosal (lung) and systemic (blood and spleen) vaccine adjuvant responses of CDG. This protocol also includes the methods to detect both humoral and cellular immune responses of CDG adjuvant. Last, this protocol can be used to study other cyclic dinucleotides as mucosal vaccine adjuvants.
Keywords: Cyclic dinucleotides (环二核苷酸)Background
Cyclic diguanylate monophosphate (CDG) is part of a new class of vaccine adjuvants called cyclic dinucleotides currently being used in clinical trials for the treatment of cancer and infectious diseases. In vitro and in vivo administration of CDG can induce strong immune responses by engaging the STING pathway to induce production of type I interferon and TNFα (McWhirter et al., 2009; Blaauboer et al., 2014). As a potential mucosal vaccine adjuvant, CDG is well known to induce protective immunity against bacterial pathogens by producing strong antibody and Th1/Th2/Th17 responses in the lung (Ebensen et al., 2007; Yan et al., 2009; Madhun et al., 2011). Mechanistically, this mucosal adjuvant acts through the lung resident dendritic cells (Blaauboer et al., 2014; Mansouri et al., 2019). To date, the cellular and molecular mechanisms of CDG have been mainly characterized by In vitro experiments with murine and human cultured cells. In vitro studies often use transfection reagents to administer CDG into cells. As CDG has two phosphate groups preventing it from directly passing through the cell membrane, the method of transfection may be artificial. Interestingly, CDG was found to be taken up by cells via pinocytosis in vivo (Blaauboer et al., 2015). This protocol describes a more physiological relevant approach to studying the adjuvant effect of CDG in vivo through intranasal immunization.
Materials and Reagents
Equipment
Procedure
文章信息
版权信息
© 2019 The Authors; exclusive licensee Bio-protocol LLC.
如何引用
Mansouri, S. and Jin, L. (2019). Evaluation of Mucosal and Systemic Vaccine Responses by Cyclic di-GMP (CDG)-adjuvanted Protein Subunit Vaccines. Bio-protocol 9(8): e3217. DOI: 10.21769/BioProtoc.3217.
分类
免疫学 > 粘膜免疫学 > 疫苗佐剂
癌症生物学 > 肿瘤免疫学 > 癌症治疗
您对这篇实验方法有问题吗?
在此处发布您的问题,我们将邀请本文作者来回答。同时,我们会将您的问题发布到Bio-protocol Exchange,以便寻求社区成员的帮助。
提问指南
+ 问题描述
写下详细的问题描述,包括所有有助于他人回答您问题的信息(例如实验过程、条件和相关图像等)。
Share
Bluesky
X
Copy link